Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: Compromise between ethics and statistics in evidence-based medicine;Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: Compromis entre éthique et statistique en médecine factuelle

Revue Medicale de Liege

Volumn 58, Issue 9, 2003, Pages 585-590

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Atorvastatin; Cholesterol; Diabetes mellitus; Evidence based medicine; Hypertension; Randomised clinical trials

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY RISK; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; MEDICAL ETHICS; REVIEW; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CLINICAL TRIALS DATA MONITORING COMMITTEES; DIABETES COMPLICATIONS; ETHICS, RESEARCH; GREAT BRITAIN; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; IRELAND; PYRROLES; RISK FACTORS; SCANDINAVIA;

EID: 0242381782     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Scheen AJ.- Evidence-based medicine. Apport des essais cliniques contrôlés. Rev. Med Liège, 2000, 55, 216-219.
2. Law MR, Wald NJ, Rudnicka AR.- Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ, 2003, 326, 1423-1427.
3. Kulbertus H, Scheen AJ.- La MRC/BHF Heart Protection Study. Rev Med Liège, 2002, 57, 613-616.
4. Kulbertus H, Scheen AJ.- L'étude ALLHAT-LLT. Rev Med Liège, 2003, 58, 53-58.
5. Scheen AJ.- Le risque cardio-vasculaire lié à l'hypercholestérolémie: d'un continuum à la notion de normalité, de seuil d'intervention et d'objectif thérapeutique. Rev Med Liège, 1999, 54, 17-21.
6. Scheen AJ, Kulbertus H.- Prévention cardio-vasculaire par les statines: faut-il encore doser le cholestérol? Rev Med Liège, 2003, 58, 191-197.
7. DeBacker G, Ambrosioni E, Borch-Johnsen K, et al.-Executive Summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J, 2003, 24, 1600-1609.
8. Scheen AJ, Lefèbvre PJ, Kulbertus H.- Comment je préviens ... les maladies cardio-vasculaires par une approche pharmacologique combinée: y a-t-il place pour une "polypill" ? Rev Med Liège, 2003, 57, 527-533.
9. Athyros VG, Papageorgiou AA, Mercouris BR.- The GReak Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr Med Res Opin, 2002, 18, 220-228.
10. Sever PS, Dahlöf B, Poulter NR, et al for the ASCOT investigators.- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361, 1149-1158.
11. Colhoun HM, Thomason MJ, Mackness MI, et al.-Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med, 2002, 9, 201-211.
12. Scheen AJ.- Editorial. Prevention of cardiovascular disease: plea for a rationale use of diet and lipid-lowering drugs. Acta Clin Belg, 2003, 58, 149-151.
13. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.- Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2000, 283, 1967-1975.
14. Furberg CD, Herrington DM, Psaty BM.- Are drugs within a class interchangeable ? Lancet, 1999, 354, 1202-1204.
15. Kennedy HL, Rosenson RS.- Physicians' interpretation of "class effects". A need for thoughtful re-evaluation. J Am Coll Cardiol, 2002, 40, 19-26.
16. McAlister FA, Laupacis A, Wells GA, et al.-Users'guides to the medical literature. XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA, 1999, 282, 1371-1377.
17. Scheen AJ.- Rhabdomyolyse fatale sous cérivastatine. Rev Med Liège, 2001, 56, 592-594.
18. Scheen AJ.- La mesure de l'efficacité thérapeutique, étape essentielle dans la médecine factuelle. Rev Med Liège, 2000, 55, 206-210.
19. éme édition). Collection statistique en biologie et médecine. Médecine-Sciences Flammarion, Paris, 1996.
20. Szczech LA, Coladonato JA, Owen WF Jr.- Key concepts in biostatistics: using statistics to answer the question "is there a difference ?". Semin Dialysis, 2002, 15, 347-351.
21. Kulbertus H, Scheen AJ.- L'étude PROSPER (PROspective Study of Pravastatin in the Elderly at Risk). Rev Med Liège, 2002, 57, 809-813.
22. Paquot N, Scheen AJ.- Prévention cardio-vasculaire chez le patient diabétique de type 2. Rev Med Liège, 2003, 58, 271-274.
23. Scheen AJ, Estrella F.- L'étude Steno-2: plaidoyer pour une prise en charge globale et intensive du patient diabétique de type 2. Rev Med Liège, 2003, 58, 109-111.
24. Gotto AM.- Lipid management in diabetic patients: lessons from prevention trials. Am J Med, 2002, 112 (Suppl 8A), 19S-26S.
25. Heart Protection Study Collaborative Group.-MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2003, 361, 2005-2016.
26. Ioannidis JPA.- Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA, 1998, 279, 281-286.
27. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation, 2000, 102, 21-27.
28. Melander H, Ahlqvist-Rasstad J, Meijer G, Beermann B.- Evidence b(i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ, 2003, 326, 1171-1173.
29. Scheen AJ.- Comment j'explore ... les secrets d'une méta-analyse. Rev Med Liège, 2003, 58, 41-46.